← Leaderboards
Choukri Ben Mamoun
University Of Connecticut Sch Of Med/Dnt
$12,993,342
Attributed
$16,737,433
Total exposure
19
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,737,433 · 19
By mechanism
R01$14,048,964 · 5
R21$1,780,427 · 4
R56$874,372 · 1
M01$33,670 · 9
Top collaborators
- Karine Gaelle Le Roch5 shared
- Christopher D Vanderwal5 shared
- Adalgisa Caccone2 shared
- Maria Ana Diuk-Wasser2 shared
- Joseph Stone Doggett1 shared
- Fatah Kashanchi1 shared
- Robert Molestina1 shared
- Michael Kevin Riscoe1 shared
Others in their field
Top investigators on “Malaria”
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$82,291,297
- Stephen Lev Hoffman · Sanaria, Inc.$79,440,588
- Constance Ann Benson · University Of California, San Diego$65,790,143
- David Heimbrook · Leidos Biomedical Research, Inc.$61,561,099
Research focus
MalariaParasitesErythrocytesPharmaceutical PreparationsInfectionFutureDesignPlasmodium FalciparumReportingUnited StatesCombined Modality TherapyDosePropertyBorrelia MicrotiBaseIn VitroBabesiosisBlack-Legged TickIn VivoBabesia MicrotiBloodTicksAntimalarialsBlood Transfusion
Grant awards (43)
Fosinopril analogs for the treatment of human babesiosis$725,898
R01 · FY2025 · AI · contact PI
Parasite-Derived Vesicles in Babesia virulence and Vaccine Development$874,372
R56 · FY2024 · AI · contact PI
Fosinopril analogs for the treatment of human babesiosis$725,898
R01 · FY2024 · AI · contact PI
Antigen Discovery and Vaccine Development for Human Babesia Parasites$418,750
R01 · FY2024 · AI · contact PI
Fosinopril analogs for the treatment of human babesiosis$725,898
R01 · FY2023 · AI · contact PI
Antigen Discovery and Vaccine Development for Human Babesia Parasites$418,750
R01 · FY2023 · AI · contact PI
Fosinopril analogs for the treatment of human babesiosis$725,898
R01 · FY2022 · AI · contact PI
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment$699,861
R01 · FY2022 · AI
Antigen Discovery and Vaccine Development for Human Babesia Parasites$418,750
R01 · FY2022 · AI · contact PI
Fosinopril analogs for the treatment of human babesiosis$742,773
R01 · FY2021 · AI · contact PI
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment$706,539
R01 · FY2021 · AI
Antigen Discovery and Vaccine Development for Human Babesia Parasites$418,750
R01 · FY2021 · AI · contact PI
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment$712,803
R01 · FY2020 · AI
Development of endochin-like quinolones for babesiosis therapy$654,825
R01 · FY2020 · AI · contact PI
Antigen Discovery and Vaccine Development for Human Babesia Parasites$418,750
R01 · FY2020 · AI · contact PI
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment$720,613
R01 · FY2019 · AI
Development of endochin-like quinolones for babesiosis therapy$660,513
R01 · FY2019 · AI · contact PI
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment$755,448
R01 · FY2018 · AI
Development of endochin-like quinolones for babesiosis therapy$669,365
R01 · FY2018 · AI · contact PI
Development of endochin-like quinolones for babesiosis therapy$688,626
R01 · FY2017 · AI · contact PI
Function and Inhibition of Plasmodium Lipid Decarboxylases$409,485
R01 · FY2016 · AI · contact PI
Probing the natural genomic diversity of Babesia microti$249,750
R21 · FY2016 · AI
Function and Inhibition of Plasmodium Lipid Decarboxylases$409,682
R01 · FY2015 · AI · contact PI
Development of novel therapeutics for Babesia microti infection$249,750
R21 · FY2015 · AI · contact PI
Probing the natural genomic diversity of Babesia microti$208,125
R21 · FY2015 · AI
Function and Inhibition of Plasmodium Lipid Decarboxylases$409,836
R01 · FY2014 · AI · contact PI
Development of novel therapeutics for Babesia microti infection$208,125
R21 · FY2014 · AI · contact PI
Function and Inhibition of Plasmodium Lipid Decarboxylases$385,421
R01 · FY2013 · AI · contact PI
Function and Inhibition of Plasmodium Lipid Decarboxylases$425,832
R01 · FY2012 · AI · contact PI
Transcriptional Regulators of the Malarial var Multigene Family$206,973
R21 · FY2011 · AI · contact PI
Transcriptional Regulators of the Malarial var Multigene Family$258,954
R21 · FY2010 · AI · contact PI
NUCLEOSIDE TRANSPORTERS$2,866
M01 · FY2008 · RR · contact PI
MALARIA$2,456
M01 · FY2008 · RR · contact PI
NUCLEOSIDE TRANSPORTERS$4,078
M01 · FY2007 · RR · contact PI
MALARIA$2,509
M01 · FY2007 · RR · contact PI
TRANSPOSON-BASED FUNCTIONAL ANALYSIS$2,039
M01 · FY2007 · RR · contact PI
MALARIA$4,914
M01 · FY2006 · RR · contact PI
NUCLEOSIDE TRANSPORTERS$4,914
M01 · FY2006 · RR · contact PI
TRANSPOSON-BASED FUNCTIONAL ANALYSIS$2,313
M01 · FY2006 · RR · contact PI
Tranposon-Based Functional Analysis of Malaria Genome$217,500
R21 · FY2005 · AI
MALARIA$2,805
M01 · FY2005 · RR
Tranposon-Based Functional Analysis of Malaria Genome$181,250
R21 · FY2004 · AI
Malaria$4,776
M01 · FY2004 · RR